loading
Fate Therapeutics Inc stock is traded at $1.07, with a volume of 767.00K. It is down -2.73% in the last 24 hours and down -6.14% over the past month. Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
See More
Previous Close:
$1.10
Open:
$1.1
24h Volume:
767.00K
Relative Volume:
0.44
Market Cap:
$122.63M
Revenue:
$13.45M
Net Income/Loss:
$-178.23M
P/E Ratio:
-0.6485
EPS:
-1.65
Net Cash Flow:
$-132.53M
1W Performance:
-13.71%
1M Performance:
-6.14%
6M Performance:
-17.69%
1Y Performance:
-78.07%
1-Day Range:
Value
$1.06
$1.11
1-Week Range:
Value
$1.06
$1.3495
52-Week Range:
Value
$0.6611
$4.655

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
Name
Fate Therapeutics Inc
Name
Phone
858.875.1803
Name
Address
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
Employee
181
Name
Twitter
@fatethx
Name
Next Earnings Date
2025-08-01
Name
Latest SEC Filings
Name
FATE's Discussions on Twitter

Compare FATE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
FATE
Fate Therapeutics Inc
1.07 126.10M 13.45M -178.23M -132.53M -1.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.13 117.32B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.87 58.89B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
401.80 51.14B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
673.80 41.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.01 32.59B 3.81B -644.79M -669.77M -6.24

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-18-24 Upgrade BofA Securities Underperform → Neutral
Jun-17-24 Upgrade Piper Sandler Neutral → Overweight
Mar-27-23 Resumed Wells Fargo Equal Weight
Jan-24-23 Downgrade H.C. Wainwright Buy → Neutral
Jan-06-23 Downgrade BMO Capital Markets Outperform → Market Perform
Jan-06-23 Downgrade BofA Securities Buy → Underperform
Jan-06-23 Downgrade Cowen Outperform → Market Perform
Jan-06-23 Downgrade Piper Sandler Overweight → Neutral
Jan-06-23 Downgrade Stifel Buy → Hold
Jan-06-23 Downgrade Truist Buy → Hold
Jan-06-23 Downgrade Wedbush Outperform → Neutral
Jan-03-23 Downgrade Guggenheim Buy → Neutral
Dec-22-22 Downgrade Oppenheimer Outperform → Perform
Dec-15-22 Initiated Goldman Sell
Nov-04-22 Resumed Cantor Fitzgerald Overweight
Oct-10-22 Initiated Canaccord Genuity Buy
Aug-18-22 Resumed Wells Fargo Overweight
Jul-28-22 Initiated Needham Hold
Jul-11-22 Upgrade BMO Capital Markets Market Perform → Outperform
Jun-03-22 Initiated Robert W. Baird Neutral
Feb-11-22 Resumed BMO Capital Markets Market Perform
Dec-15-21 Upgrade Wedbush Neutral → Outperform
Dec-07-21 Initiated Cowen Outperform
Nov-09-21 Upgrade Citigroup Neutral → Buy
Aug-26-21 Initiated Morgan Stanley Equal-Weight
Jun-07-21 Upgrade H.C. Wainwright Neutral → Buy
May-07-21 Upgrade Wedbush Neutral → Outperform
Apr-26-21 Resumed Jefferies Buy
Feb-26-21 Initiated BofA Securities Buy
Feb-26-21 Downgrade Wedbush Outperform → Neutral
Feb-11-21 Downgrade Citigroup Buy → Neutral
Jan-27-21 Resumed H.C. Wainwright Neutral
May-13-20 Initiated H.C. Wainwright Buy
Mar-04-20 Initiated Barclays Overweight
Jan-09-20 Downgrade BMO Capital Markets Outperform → Market Perform
Dec-30-19 Reiterated Mizuho Buy
Dec-09-19 Upgrade Wells Fargo Market Perform → Outperform
Nov-12-19 Initiated SunTrust Buy
Nov-06-19 Downgrade Wells Fargo Outperform → Market Perform
Oct-01-19 Initiated Stifel Buy
Aug-09-19 Initiated BTIG Research Buy
Jul-22-19 Initiated Cantor Fitzgerald Overweight
Jul-12-19 Initiated Oppenheimer Outperform
Jun-13-19 Initiated Mizuho Buy
Jun-07-19 Initiated ROTH Capital Neutral
May-31-19 Initiated Guggenheim Buy
May-24-19 Resumed Citigroup Buy
Mar-28-19 Initiated SVB Leerink Outperform
Jan-03-19 Downgrade Stephens Overweight → Equal-Weight
Nov-05-18 Initiated Jefferies Buy
Aug-01-18 Initiated Citigroup Buy
Mar-06-18 Downgrade H.C. Wainwright Buy → Neutral
View All

Fate Therapeutics Inc Stock (FATE) Latest News

pulisher
Aug 01, 2025

Fate Therapeutics’ Phase 1 Study: A New Hope for Autoimmune Diseases - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

Is Fate Therapeutics Inc. a growth stock or a value stockAdvanced Screener Ideas For Fast Growth - jammulinksnews.com

Aug 01, 2025
pulisher
Jul 31, 2025

What are Fate Therapeutics Inc. company’s key revenue driversStock Market Data Feed For Consistent Profits - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 31, 2025

What is the dividend policy of Fate Therapeutics Inc. stockWealth Building Guidance For Smart Trading - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 31, 2025

How does Fate Therapeutics Inc. generate profit in a changing economyFinancial News Forecasts For Smart Trading - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 31, 2025

How volatile is Fate Therapeutics Inc. stock compared to the marketTop Growth Tracker With Low Risk - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 30, 2025

Published on: 2025-07-30 19:50:13 - metal.it

Jul 30, 2025
pulisher
Jul 30, 2025

Published on: 2025-07-30 17:10:31 - beatles.ru

Jul 30, 2025
pulisher
Jul 30, 2025

Published on: 2025-07-30 08:12:45 - metal.it

Jul 30, 2025
pulisher
Jul 29, 2025

What makes Fate Therapeutics Inc. stock price move sharplyReliable Alerts for Daily Stock Movers Released - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

How Resilient Is Fate Therapeutics Inc. Stock During Economic DownturnsDaily Smart Money Movement Monitor Activated - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Why Fate Therapeutics Inc. stock attracts strong analyst attentionStock Market Watch With Alerts Shows Unusual Activity - beatles.ru

Jul 29, 2025
pulisher
Jul 29, 2025

Trapped Investors in Fate Therapeutics Inc. Await Breakout SignalSector Based Breakout Stock Forecast Issued - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

What is Fate Therapeutics Inc. company’s growth strategyBest Dividend Report From AI Tools - jammulinksnews.com

Jul 29, 2025
pulisher
Jul 28, 2025

How strong is Fate Therapeutics Inc. company’s balance sheetHigh-profit stock alerts - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Ranking Fate Therapeutics Inc. among high performing stocks via toolsWeekly Gain Forecast with Momentum Indicators - Newser

Jul 28, 2025
pulisher
Jul 28, 2025

Can Fate Therapeutics Inc. stock recover from recent declineLong Term Safe Yield Focus - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

Does Fate Therapeutics Inc. stock perform well during market downturnsPhenomenal capital gains - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

What institutional investors are buying Fate Therapeutics Inc. stockConsistently outstanding ROI - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Is Fate Therapeutics Inc. stock overvalued or undervaluedAchieve fast wealth growth with smart picks - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are analysts’ price targets for Fate Therapeutics Inc. in the next 12 monthsDiscover stocks with massive upside potential - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Will Fate Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsDaily Price Surge List - metal.it

Jul 27, 2025
pulisher
Jul 27, 2025

Has Fate Therapeutics Inc. Stock Ever Crashed Historical Volatility ReviewFree Investment Group - Newser

Jul 27, 2025
pulisher
Jul 25, 2025

What drives Fate Therapeutics Inc. stock priceFree Market Dynamics Reports - Autocar Professional

Jul 25, 2025
pulisher
Jul 24, 2025

How Fate Therapeutics Inc. stock performs during market volatilityHigh Accuracy Alerts - Newser

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Fate Therapeutics Inc. stockSkyrocketing investment returns - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Is Fate Therapeutics Inc. a good long term investmentExceptional gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Fate Therapeutics Inc. Stock Analysis and ForecastLightning-fast capital gains - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 18, 2025

why fate therapeutics inc. stock attracts strong analyst attentionFree Day Trading Recommendations - Newser

Jul 18, 2025

Fate Therapeutics Inc Stock (FATE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.59
price up icon 0.93%
$37.11
price up icon 0.84%
$108.69
price up icon 1.31%
$27.07
price up icon 2.65%
$107.34
price down icon 0.15%
biotechnology ONC
$299.01
price down icon 0.70%
Cap:     |  Volume (24h):